ZEISS Group, founded in 1846 and headquartered in Oberkochen, Germany, is a global technology leader in optics and optoelectronics, renowned for its pioneering innovations in medical technology, semiconductor manufacturing, microscopy, and metrology. The company designs and manufactures a wide array of solutions including eyeglass lenses, camera lenses, binoculars, surgical microscopes, and lithography systems for chip production. ZEISS serves industries such as healthcare, life sciences, industrial quality assurance, and consumer electronics, with a strong focus on precision engineering, research partnerships, and sustainability. It operates in over 50 countries with a global workforce exceeding 35,000 employees.
The extended partnership advances sub-2nm semiconductor R&D, enhances Europe's innovation leadership, supports imec’s pilot line, and aligns with the European Chips Act.
This innovative solution combines precise measurement technology with high-resolution microscopic inspection, enabling the examination of both large and small components in a single device.
ZEISS Medical Technology has announced the U.S. Food and Drug Administration (FDA) has cleared the QUATERA® 700*, a revolution in phaco technology. It includes the ZEISS patented QUATTRO Pump® which delivers an exceptional level of chamber stability independent of intra-ocular pressure (IOP) and flow.
ZEISS Group and Microsoft Corp. announced a multi-year strategic partnership to accelerate ZEISS' transformation into a digital services provider that is embracing a cloud-first approach. By standardizing its equipment and processes on Microsoft Azure as its preferred cloud platform, ZEISS will be able to provide its customers with enhanced digital experiences, address changing market needs more quickly and increase its productivity.